KR100507715B1 - 프로사포신계펩티드를이용한신경병증성통증경감방법 - Google Patents

프로사포신계펩티드를이용한신경병증성통증경감방법 Download PDF

Info

Publication number
KR100507715B1
KR100507715B1 KR1019980707151A KR19980707151A KR100507715B1 KR 100507715 B1 KR100507715 B1 KR 100507715B1 KR 1019980707151 A KR1019980707151 A KR 1019980707151A KR 19980707151 A KR19980707151 A KR 19980707151A KR 100507715 B1 KR100507715 B1 KR 100507715B1
Authority
KR
South Korea
Prior art keywords
seq
prosaposin
peptide
neuropathic pain
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019980707151A
Other languages
English (en)
Korean (ko)
Other versions
KR19990087686A (ko
Inventor
존 에스 오브리엔
Original Assignee
리전츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리전츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 리전츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR19990087686A publication Critical patent/KR19990087686A/ko
Application granted granted Critical
Publication of KR100507715B1 publication Critical patent/KR100507715B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019980707151A 1996-03-05 1997-03-05 프로사포신계펩티드를이용한신경병증성통증경감방법 Expired - Fee Related KR100507715B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
US08/611,307 1996-03-05
US8/611,307 1996-03-05

Publications (2)

Publication Number Publication Date
KR19990087686A KR19990087686A (ko) 1999-12-27
KR100507715B1 true KR100507715B1 (ko) 2006-05-26

Family

ID=24448513

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980707151A Expired - Fee Related KR100507715B1 (ko) 1996-03-05 1997-03-05 프로사포신계펩티드를이용한신경병증성통증경감방법

Country Status (16)

Country Link
US (2) US6271196B1 (enExample)
EP (1) EP0929569B1 (enExample)
JP (1) JP4138006B2 (enExample)
KR (1) KR100507715B1 (enExample)
AT (1) ATE340187T1 (enExample)
AU (1) AU734566B2 (enExample)
CA (1) CA2248139C (enExample)
CZ (1) CZ297384B6 (enExample)
DE (1) DE69736712T2 (enExample)
IL (1) IL126082A0 (enExample)
NO (1) NO984093L (enExample)
NZ (1) NZ331757A (enExample)
PL (1) PL187917B1 (enExample)
RU (2) RU2223969C2 (enExample)
SK (1) SK122898A3 (enExample)
WO (1) WO1997032895A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHOD FOR HEALING NEUROPATHIC PAIN
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
AU9774698A (en) * 1997-09-09 1999-03-29 Regents Of The University Of California, The Inhibition of apoptotis using prosaposin receptor agonists
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
AU751034B2 (en) * 1998-08-28 2002-08-08 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
IL145527A0 (en) * 1999-03-30 2002-06-30 Myelos Corp Retro-inverso prosaposin-derived peptides and use thereof
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
WO2000077028A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-3
WO2000077029A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
WO2000077033A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
DK1605965T3 (da) * 2003-03-26 2013-04-15 Evotec Internat Gmbh Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom
JP2006521399A (ja) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
SG10201604530SA (en) 2008-01-22 2016-07-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
WO2012115185A1 (ja) * 2011-02-23 2012-08-30 北海道公立大学法人札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
CN114642720A (zh) 2018-03-23 2022-06-21 百祥制药公司 皂化蛋白c药物组合物和治疗癌症的方法
EP3774848B1 (en) 2018-03-29 2023-02-22 Lateral Ip Pty Ltd Cyclic peptides and uses thereof
US20240316146A1 (en) * 2021-01-09 2024-09-26 Bexion Pharmaceuticals Inc Methods of reducing neuropathy and neuropathic symptoms and treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108459T1 (de) 1986-04-22 1994-07-15 Salk Inst For Biological Studi Antagonisten des fibroblasten-wachstumsfaktors.
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHOD FOR HEALING NEUROPATHIC PAIN
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides

Also Published As

Publication number Publication date
DE69736712D1 (de) 2006-11-02
NO984093D0 (no) 1998-09-04
ATE340187T1 (de) 2006-10-15
NO984093L (no) 1998-11-04
AU734566B2 (en) 2001-06-14
SK122898A3 (en) 2000-02-14
PL328701A1 (en) 1999-02-15
US6271196B1 (en) 2001-08-07
WO1997032895A1 (en) 1997-09-12
NZ331757A (en) 1999-10-28
US6268347B1 (en) 2001-07-31
EP0929569A4 (en) 2000-08-23
DE69736712T2 (de) 2007-09-13
CA2248139C (en) 2004-05-18
PL187917B1 (pl) 2004-11-30
CA2248139A1 (en) 1997-09-12
JP4138006B2 (ja) 2008-08-20
CZ297384B6 (cs) 2006-11-15
IL126082A0 (en) 1999-05-09
EP0929569A1 (en) 1999-07-21
RU2003131695A (ru) 2005-04-10
RU2266129C2 (ru) 2005-12-20
AU2328697A (en) 1997-09-22
KR19990087686A (ko) 1999-12-27
EP0929569B1 (en) 2006-09-20
CZ283998A3 (cs) 1999-05-12
RU2223969C2 (ru) 2004-02-20
JP2000506853A (ja) 2000-06-06

Similar Documents

Publication Publication Date Title
KR100507715B1 (ko) 프로사포신계펩티드를이용한신경병증성통증경감방법
AU751034B2 (en) Cyclic prosaposin-derived peptides and uses thereof
US6849602B1 (en) Compositions for alleviating neuropathic pain with prosaposin receptor agonists
KR102075881B1 (ko) 이질통, 통각과민증, 자발통 및 환상통의 치료
CA2282827A1 (en) Method of alleviating neuropathic pain
CA2300221A1 (en) Retro-inverso neurotrophic and analgesic peptides
US12220442B2 (en) Antiepileptic toxin Martentoxin and use thereof
CA2284105A1 (en) Synthetic saposin c-derived neurotrophic peptides
WO1998042746A9 (en) Synthetic saposin c-derived neurotrophic peptides
AU2002300005B2 (en) Method of alleviating neuropathic pain
AU4267297A (en) Method of alleviating neuropathic pain
MXPA98007245A (en) Methods to alleviate neuropathic pain using peptides derived from prosapos
CA2113815A1 (en) Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage
CN1224430A (zh) 利用prosaposin衍生多肽缓解神经性疼痛的方法
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080804

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080804